Omalizumab, a monoclonal antibody that targets IgE, is approved by the United States Food and Drug Administration for the treatment of CRSwNP based on the results of the phase 3 POLYP-1 and POLYP-2 studies (90). This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.